icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
 
 
 
Arrowhead Pharmaceuticals Announces Presentations
at The International Liver Congress™

 
 
  PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical data on ARC-520, ARC-521, and ARC-AAT, the company's prior generation investigational medicines that were being studied for the treatment of chronic hepatitis B infection and liver disease associated with alpha-1 antitrypsin deficiency, at The International Liver Congress™ 2017 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL) being held in Amsterdam, the Netherlands from April 19-23, 2017.
 
Oral Presentations:
 
Prolonged RNA interference therapy with ARC-520 Injection in treatment na´ve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen

 
⋅Presentation Reference: PS-045
⋅Session: Parallel session: Hepatitis B and D: Emerging treatment options
⋅Date and Time: April 20, 2017 at 5:30 PM CET
⋅Authors: Man-Fung Yuen, et al.
 
Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients
 
⋅Presentation Reference: LBO-06
⋅Session: Late Breaker session
⋅Date and Time: April 22, 2017 at 5:15 PM CET
⋅Authors: Alice Turner, et al.
 
Poster Presentation:
 
A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer population

 
⋅Presentation Reference: THU-176
⋅Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new compounds, resistance)
⋅Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
⋅Authors: Edward Gane, et al.
 
Additional details including presentation abstracts can be found on the ILC website at https://ilc-congress.eu/. A copy of presentation materials can be accessed by visiting the Events section of the Arrowhead website after the presentations conclude.
 
Arrowhead announced on November 29, 2016 that it had discontinued development of ARC-520, ARC-521, and ARC-AAT. The company continues to develop ARO-HBV and ARO-AAT, which are follow on investigational RNAi therapeutics against chronic hepatitis B infection and alpha-1 liver disease that utilize the company's new proprietary subcutaneous delivery system.
 
The International Liver Congress is a trademark of the European Association for the Study of the Liver.
 
About Arrowhead Pharmaceuticals
 
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
 
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.
 
Safe Harbor Statement under the Private Securities Litigation Reform Act:
 
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
 
Source: Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.

 
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
 
or
Investor Relations:
 
The Trout Group
Chad Rubin, 646-378-2947
ir@arrowheadpharma.com
or
 
Media:
Russo Partners
Rich Allan, 646-942-5588
rich.allan@russopartnersllc.com
Source: Arrowhead Pharmaceuticals, Inc.